Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently announced the planned pivotal Phase 3 study design of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), a topical mTOR …
Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN 3.9% Rapamycin Anhydrous Gel Read More WAYNE, PA — Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently announced topline results from VAPAUS, a 24-week, randomized, double-blind, placebo-controlled pivotal Phase 3 study of QTORIN™ 3.9% rapamycin anhydrous …
Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN 3.9% Rapamycin Anhydrous Gel Read More WAYNE, PA — Palvella Therapeutics, Inc. this week announced positive topline results from the Company’s Phase 2 study of QTORIN™ rapamycin in Microcystic Lymphatic Malformations (Microcystic LM). Microcystic LM is …
Positive Results from QTORIN Study for Microcystic LM Read More WAYNE, PA — Palvella Therapeutics, Inc. this week reported progress on its three lead development programs for QTORIN™ rapamycin. The company announced that it has completed enrollment in clinical studies that …
Palvella Therapeutics Reports Progress on Three Lead Development Programs Read More WAYNE, PA — Palvella Therapeutics, Inc. announced the recent initial closing of its Series D financing of up to $37.7 million. The financing was led by Petrichor and included new …
Palvella Therapeutics, Inc. Raises $37.7 Million in Series D Financing Read More